ArticleBritish journal of haematology2026
Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time. Using the French national registry for CDs, we revisited the full spectrum of these diseases to update our current knowledge on the optimal management of these patients. The unicentric type (UCD) has usually an indolent course and can be cured by surgical resection. However, a small percentage of the UCD patients develop severe autoimmune or malignant complications. The human herpesvirus 8 (HHV8)-associated multicentric type (HHV8+ MCD) has been mainly described in human immunodeficiency virus (HIV)-infected patients but is an emerging condition outside this setting in other populations. The third type, idiopathic multicentric Castleman disease (iMCD) remains a challenging diagnosis as the pathological features observed in these patients are shared with many other conditions such as lymphoid neoplasia and systemic diseases. Other syndromes such as POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes), TAFRO (thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly), IgG4-RD (IgG4-related disease) and IPL (idiopathic plasmacytic lymphadenopathy) may also overlap with iMCD and could be considered either associated conditions or differential diagnosis. In addition, the clinical phenotype of iMCD exhibits several striking differences among populations with a much more heterogeneous pattern in Western populations than in patients of Asian ancestry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.